JP2001509661A - トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法 - Google Patents

トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法

Info

Publication number
JP2001509661A
JP2001509661A JP52698297A JP52698297A JP2001509661A JP 2001509661 A JP2001509661 A JP 2001509661A JP 52698297 A JP52698297 A JP 52698297A JP 52698297 A JP52698297 A JP 52698297A JP 2001509661 A JP2001509661 A JP 2001509661A
Authority
JP
Japan
Prior art keywords
cells
cell
library
peptide
candidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP52698297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001509661A5 (enExample
Inventor
ゲアリー ピー ノアルン
エス マイケル ローテンバーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/589,109 external-priority patent/US6365344B1/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2001509661A publication Critical patent/JP2001509661A/ja
Publication of JP2001509661A5 publication Critical patent/JP2001509661A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP52698297A 1996-01-23 1997-01-23 トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法 Ceased JP2001509661A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58991196A 1996-01-23 1996-01-23
US08/589,109 US6365344B1 (en) 1996-01-23 1996-01-23 Methods for screening for transdominant effector peptides and RNA molecules
US08/589,911 1996-01-23
US08/589,109 1996-01-23
PCT/US1997/001048 WO1997027213A1 (en) 1996-01-23 1997-01-23 Methods for screening for transdominant effector peptides and rna molecules

Publications (2)

Publication Number Publication Date
JP2001509661A true JP2001509661A (ja) 2001-07-24
JP2001509661A5 JP2001509661A5 (enExample) 2004-11-11

Family

ID=27080449

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52698297A Ceased JP2001509661A (ja) 1996-01-23 1997-01-23 トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法
JP9526969A Pending JP2000504220A (ja) 1996-01-23 1997-01-23 トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP9526969A Pending JP2000504220A (ja) 1996-01-23 1997-01-23 トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法

Country Status (9)

Country Link
US (5) US6153380A (enExample)
EP (2) EP0877752B1 (enExample)
JP (2) JP2001509661A (enExample)
AU (2) AU1707497A (enExample)
CA (1) CA2244222A1 (enExample)
DE (1) DE69722176T2 (enExample)
DK (1) DK0877752T3 (enExample)
ES (1) ES2200150T3 (enExample)
WO (2) WO1997027212A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018518955A (ja) * 2015-06-11 2018-07-19 ジェネクシン・インコーポレイテッドＧｅｎｅｘｉｎｅ， Ｉｎｃ． 改変されたインターロイキン−７タンパク質およびその使用
US11357827B2 (en) 2015-12-04 2022-06-14 Genexine, Inc. Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein
US11548927B2 (en) 2015-11-06 2023-01-10 Genexine, Inc. Formulation of modified interleukin-7 fusion protein
US11708399B2 (en) 2015-12-04 2023-07-25 Genexine, Inc. Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6004746A (en) * 1994-07-20 1999-12-21 The General Hospital Corporation Interaction trap systems for detecting protein interactions
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
USRE45721E1 (en) 1994-08-20 2015-10-06 Gendaq, Ltd. Relating to binding proteins for recognition of DNA
US20050002902A1 (en) * 1995-12-28 2005-01-06 Liming Yu Hybrid with interferon-alpha and an immunoglobulin Fc for treatment of tumors and viral infections
JP2001509661A (ja) * 1996-01-23 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US5955275A (en) 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6623922B1 (en) 1997-02-14 2003-09-23 Deltagen Proteomics Methods for identifying, characterizing, and evolving cell-type specific CIS regulatory elements
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6969584B2 (en) 1997-06-12 2005-11-29 Rigel Pharmaceuticals, Inc. Combinatorial enzymatic complexes
DE19737562A1 (de) * 1997-08-28 1999-05-06 Otogene Biotechnologische Fors Verfahren zur Identifizierung von Wechselwirkungen zwischen Proteinen bzw. Peptiden
US6322973B1 (en) 1997-11-07 2001-11-27 Iconix Pharmaceuticals, Inc. Surrogate genetics target characterization method
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
US6475726B1 (en) 1998-01-09 2002-11-05 Cubist Pharmaceuticals, Inc. Method for identifying validated target and assay combinations for drug development
US6846625B1 (en) 1998-01-09 2005-01-25 Cubist Pharmaceuticals, Inc. Method for identifying validated target and assay combination for drug development
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
DE19805334A1 (de) * 1998-02-11 1999-08-12 Otogene Biotechnologische Fors Verfahren zur Entwicklung eines pharmazeutischen Wirkstoffes
US6803194B1 (en) 1998-02-13 2004-10-12 Hk Pharmaceuticals, Inc. Use of ribozymes for functionating genes
ATE466952T1 (de) 1998-03-02 2010-05-15 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
CA2323064C (en) 1998-03-17 2011-05-31 Gendaq Limited Nucleic acid binding proteins
AU3707099A (en) * 1998-04-08 1999-11-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Process for producing cell clone libraries
CA2327830A1 (en) * 1998-04-09 1999-10-21 Iconix Pharmaceuticals Inc. Methods for identifying genetic determinants associated with modulation of test compound activity
US6461813B2 (en) * 1998-09-21 2002-10-08 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in cell cycle regulation
US6897031B1 (en) * 1998-04-17 2005-05-24 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in exocytosis
US8334238B2 (en) * 1998-04-17 2012-12-18 Rigel, Inc. Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule libraries
US7060433B1 (en) * 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs
US7001733B1 (en) * 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
US20040002056A1 (en) * 1998-05-12 2004-01-01 Lorens James B. Methods of screening for bioactive agents using cells transformed with self-inactivating viral vectors
US7090976B2 (en) 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
DE19829495A1 (de) * 1998-07-02 2000-01-05 Jacques Paysan Reagenzien und deren Anwendung zur Untersuchung von Wechselwirkungen zwischen zellulären Molekülen und deren Lokalisation in Zellen
EA003637B1 (ru) * 1998-07-20 2003-08-28 Инокселл А/С Новые способы идентификации биомолекул лигандов и мишеней
EP1270746A1 (en) * 1998-07-20 2003-01-02 Inoxell A/S Methods for the identification of ligand and target biomolecules
US6472151B1 (en) 1998-08-19 2002-10-29 Bristol-Myers Squibb Company Method of screening for compounds that modulate the activity of a molecular target
WO2000020859A1 (en) * 1998-10-05 2000-04-13 Duke University METHOD AND APPARATUS FOR DETECTING BINDING INTERACTIONS $i(IN VIVO)
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
AU774332B2 (en) * 1999-03-12 2004-06-24 Gpc Biotech Inc. Methods and reagents for identifying synthetic genetic elements
EP1165842A4 (en) * 1999-03-16 2004-07-07 Dana Farber Cancer Inst Inc LENTIVIRAL VECTOR SYSTEM FOR LARGE QUANTITY SCREENING
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
ATE269897T1 (de) * 1999-03-29 2004-07-15 Michael Blind Methoden zur identifizierung und validierung von funktionellen zielen mittels intrameren oder in vivo selektion
US6524797B1 (en) 1999-05-10 2003-02-25 Bernhard O. Palsson Methods of identifying therapeutic compounds in a genetically defined setting
US6737240B1 (en) 1999-05-25 2004-05-18 Rigel Pharmaceuticals, Inc. Methods of screening for a multi-drug resistance conferring peptide
CA2374918A1 (en) * 1999-05-25 2000-11-30 Rigel Pharmaceuticals, Inc. Identification of novel mechanisms of drug resistance
EP1055929A1 (en) 1999-05-26 2000-11-29 Tibotec N.V. Means and methods for drug discovery and the phenotypic characterisation of cells
IL146743A0 (en) * 1999-05-31 2002-07-25 Novozymes As Screening method for peptides
AU2005209649B2 (en) * 1999-05-31 2008-05-29 Novozymes A/S Screening method for peptides
AU2041901A (en) 1999-11-09 2001-06-06 Elitra Pharmaceuticals, Inc. Genes essential for microbial proliferation and antisense thereto
DE60032927T2 (de) * 1999-11-10 2007-11-08 Rigel Pharmaceuticals, Inc., South San Francisco Verfahren and zusammenstellungen, die renilla gfp enthalten
AU768827B2 (en) * 1999-12-28 2004-01-08 Esbatech, An Alcon Biomedical Research Unit Llc Intrabodies with defined framework that is stable in a reducing environment and applications thereof
AU2001226935B2 (en) 2000-01-24 2006-06-22 Gendaq Limited Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
US6582899B1 (en) * 2000-02-15 2003-06-24 Deltagen Proteomics, Inc. Methods for identifying agents that cause a lethal phenotype, and agents thereof
US7378248B2 (en) * 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
EP1263777A2 (en) * 2000-03-06 2002-12-11 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides
US7252952B2 (en) * 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US7566765B2 (en) * 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
AU2001289284A1 (en) * 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
US6762031B2 (en) * 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
IL154210A0 (en) * 2000-07-31 2003-07-31 Univ Bar Ilan Methods and pharmaceutical compositions for healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
DE10060959A1 (de) * 2000-12-06 2002-06-20 Aventis Res & Tech Gmbh & Co Verfahren zur Isolierung und Identifizierung von Effektoren
WO2002046412A2 (en) 2000-12-07 2002-06-13 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
ES2409080T3 (es) 2001-01-22 2013-06-24 Sangamo Biosciences Inc. Proteínas de unión con dedos de zinc modificadas
AU2002338446A1 (en) * 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
WO2002062822A2 (en) * 2001-02-02 2002-08-15 University Of Rochester Methods of identifying regulator molecules
US20030175685A1 (en) * 2001-02-22 2003-09-18 Praecis Pharmaceuticals Inc. Methods for identifying peptides which modulate a biological process
IL142481A0 (en) * 2001-04-05 2002-03-10 Yissum Res Dev Co A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
DE10119999A1 (de) * 2001-04-23 2002-10-24 Univ Heidelberg Verfahren zur Identifizierung und Entwicklung von Substanzen oder Substanzgemischen die zelluläre Transport-, Prozessierungs- und Sekretionsprozesse beeinflussen
US20050255464A1 (en) * 2001-07-19 2005-11-17 Hagen Frederick S Methods for the identification of peptidyl compounds interacting with extracellular target molecules
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CA2461315A1 (en) * 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
CA2466172C (en) * 2001-11-01 2010-07-27 Rensselaer Polytechnic Institute Biocatalytic solgel microarrays
WO2003040168A2 (en) * 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US20070128657A1 (en) 2002-01-23 2007-06-07 El-Gewely Mohamed R Molecular libraries
CA2479730A1 (en) 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20030219723A1 (en) * 2002-05-20 2003-11-27 Lu Henry H. Compositions and methods for screening and identifying anti-HCV agents
CN100335630C (zh) * 2002-06-07 2007-09-05 索菲昂生物科学有限公司 筛选方法
JP2005529624A (ja) * 2002-06-21 2005-10-06 シノゲノマックス カンパニー リミテッド ランダムｄｎａライブラリーと二本鎖ｒｎａライブラリー、その用途および生産方法
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
AU2003269851A1 (en) * 2002-10-09 2004-05-04 Novozymes A/S A method for screening for an antimicrobial polypeptide
WO2004041213A2 (en) * 2002-11-04 2004-05-21 Bioarctic Neuroscience Ab Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
US20060275833A1 (en) * 2002-11-04 2006-12-07 Icogenex Corporation Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
CA2516138A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20050002962A1 (en) * 2003-04-16 2005-01-06 David Pasco Immunostimulatory agents in botanicals
EP1625394A4 (en) * 2003-04-23 2008-02-06 Bioseek Inc METHOD FOR ANALYZING BIOLOGICAL DATA PROFILES
GB0313173D0 (en) * 2003-06-07 2003-07-16 Givaudan Sa Improvements in or related to organic compounds
NZ573737A (en) * 2003-07-15 2011-06-30 Univ Bar Ilan Methods and pharmaceutical compositions for healing wounds comprising a PKC modulator
US7776584B2 (en) * 2003-08-01 2010-08-17 Genetix Limited Animal cell colony picking apparatus and method
CN101287483B (zh) * 2003-08-07 2012-02-29 希尔洛有限公司 用于加速伤口愈合的药物组合物和方法
US20050052687A1 (en) * 2003-08-12 2005-03-10 Murata Kikai Kabushiki Kaisha Image processing device and communication terminal device
EP1730288B1 (en) * 2004-03-22 2013-05-15 The Ohio State University Research Foundation Methods for transfecting natural killer cells
US7745196B1 (en) 2004-03-25 2010-06-29 Rigel Pharmaceuticals, Inc. Methods and compositions for identifying peptide modulators of cell surface receptors
EP1749022A2 (en) * 2004-05-24 2007-02-07 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
DK1751181T3 (da) 2004-06-02 2012-11-26 Adalta Pty Ltd BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER
WO2006039630A2 (en) * 2004-10-02 2006-04-13 Indiana University Research & Technology Corporation Materials and methods for identifying compounds that modulate the cell cycle
NZ562453A (en) 2005-03-31 2010-04-30 Agensys Inc Antibodies and related molecules that bind to 161P2F10B proteins
EP2062591A1 (en) 2005-04-07 2009-05-27 Novartis Vaccines and Diagnostics, Inc. CACNA1E in cancer diagnosis detection and treatment
JP2008535494A (ja) 2005-04-07 2008-09-04 サグレシュ ディスカバリー， インコーポレイテッド 癌関連遺伝子（ｐｒｌｒ）
EP2452691A3 (en) * 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention of diabetic and aged skin
JP4959710B2 (ja) * 2005-11-01 2012-06-27 レンセレアー ポリテクニック インスティテュート 毒物学アッセイのための３次元細胞アレイチップおよびプラットフォーム
US8242057B2 (en) * 2006-06-26 2012-08-14 Cleveland Biolabs, Inc. Methods for identifying modulators of apoptosis
KR20130121678A (ko) * 2007-07-30 2013-11-06 힐로 리미티드 약제학적 조성물 및 관련 방법
MX2011007970A (es) * 2009-02-24 2011-10-19 Healor Ltd Agentes terapeuticos de visfatina para el tratamiento de acne y otras condiciones.
WO2010129310A1 (en) * 2009-04-27 2010-11-11 Roswell Park Cancer Institute Reagents and methods for producing bioactive secreted peptides
WO2010136485A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2773743B1 (en) 2011-11-04 2019-05-22 Bio-Rad Laboratories, Inc. Affinity methods and compositions employing electronic control of ph
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
EP2812349B1 (en) 2012-02-10 2021-09-01 Cambridge Enterprise Limited Methods for the characterisation of interaction sites on target proteins
WO2013163631A2 (en) 2012-04-27 2013-10-31 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
GB2505237A (en) * 2012-08-24 2014-02-26 Stefan Grimm Method of screening for therapeutic agents using cell lines including a reference cell line
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US10519207B2 (en) 2015-06-12 2019-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for treating opioid tolerance
EP4281557A4 (en) * 2021-01-19 2025-03-19 Hope Patents, LLC A method for identifying peptide therapeutics to treat a variety of conditions

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618578A (en) 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
DE3546806C2 (enExample) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5266464A (en) 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5688655A (en) 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US4980281A (en) 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
CN1038306A (zh) 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
DE68927933T2 (de) * 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
JP3043407B2 (ja) 1990-02-15 2000-05-22 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 完全合成アフィニティ試薬
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
ATE143056T1 (de) 1990-05-01 1996-10-15 Isis Pharmaceuticals Inc Identifikation von neuen medikamenten und reagenzien
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
JP3378962B2 (ja) 1991-08-07 2003-02-17 アンダースン，ダブリュー．，フレンチ 内部リボソームエントリー部位を含むレトロウイルスベクター
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
EP0670905B1 (en) * 1992-09-22 2003-07-23 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
WO1994018219A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US6140120A (en) * 1993-02-12 2000-10-31 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
JP3866760B2 (ja) * 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
WO1994020608A1 (en) 1993-03-12 1994-09-15 Creighton University Improved vectors for gene therapy
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
JPH09500625A (ja) * 1993-07-09 1997-01-21 スミスクライン・ビーチャム・コーポレイション 環状セミランダムペプチドライブラリー
WO1995004824A1 (en) * 1993-08-05 1995-02-16 Medvet Science Pty. Ltd. Generation of dna libraries and retroviral vectors for same
AU8091694A (en) 1993-10-26 1995-05-22 United Biomedical Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US6303574B1 (en) * 1994-07-22 2001-10-16 The University Of North Carolina At Chapel Hill Scr SH3 binding peptides and methods of isolating and using same
WO1996023899A1 (en) * 1995-02-01 1996-08-08 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
CA2222879A1 (en) * 1995-06-02 1996-12-05 M&E Biotech A/S A method for identification of biologically active peptides and nucleic acids
US20010053523A1 (en) 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
EP0873049B1 (en) * 1995-09-29 2006-05-10 Indiana University Research and Technology Corporation Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains
JP2001509661A (ja) * 1996-01-23 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法
US5955275A (en) * 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
EA003637B1 (ru) 1998-07-20 2003-08-28 Инокселл А/С Новые способы идентификации биомолекул лигандов и мишеней

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018518955A (ja) * 2015-06-11 2018-07-19 ジェネクシン・インコーポレイテッドＧｅｎｅｘｉｎｅ， Ｉｎｃ． 改変されたインターロイキン−７タンパク質およびその使用
US10844104B2 (en) 2015-06-11 2020-11-24 Genexine, Inc. Modified interleukin-7 protein
US11041007B2 (en) 2015-06-11 2021-06-22 Genexine, Inc. Modified interleukin-7 protein
US11548927B2 (en) 2015-11-06 2023-01-10 Genexine, Inc. Formulation of modified interleukin-7 fusion protein
US12344647B2 (en) 2015-11-06 2025-07-01 Genexine, Inc. Formulation of modified interleukin-7 fusion protein
US11357827B2 (en) 2015-12-04 2022-06-14 Genexine, Inc. Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein
US11708399B2 (en) 2015-12-04 2023-07-25 Genexine, Inc. Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases
US12357677B2 (en) 2015-12-04 2025-07-15 Genexine, Inc. Virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein
US12479898B2 (en) 2015-12-04 2025-11-25 Genexine, Inc. Pharmaceutical composition comprising immunoglobulin fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases

Also Published As

Publication number Publication date
ES2200150T3 (es) 2004-03-01
AU1707497A (en) 1997-08-20
WO1997027213A1 (en) 1997-07-31
AU725716B2 (en) 2000-10-19
US20030104384A1 (en) 2003-06-05
EP1295952A2 (en) 2003-03-26
US6455247B1 (en) 2002-09-24
US20020146710A1 (en) 2002-10-10
JP2000504220A (ja) 2000-04-11
US20020127564A1 (en) 2002-09-12
EP0877752B1 (en) 2003-05-21
DE69722176T2 (de) 2004-03-18
AU1707897A (en) 1997-08-20
US6153380A (en) 2000-11-28
DE69722176D1 (de) 2003-06-26
CA2244222A1 (en) 1997-07-31
WO1997027212A1 (en) 1997-07-31
AU725716C (en) 2003-02-20
EP1295952A3 (en) 2003-07-09
DK0877752T3 (da) 2003-09-15
EP0877752A1 (en) 1998-11-18
HK1016997A1 (en) 1999-11-12
US6737241B2 (en) 2004-05-18

Similar Documents

Publication Publication Date Title
JP2001509661A (ja) トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法
US7056687B2 (en) Methods and compositions for screening for altered cellular phenotypes
US6180343B1 (en) Green fluorescent protein fusions with random peptides
US6969584B2 (en) Combinatorial enzymatic complexes
US20050032110A1 (en) Directionally cloned random cDNA expression vector libraries, compositions and methods of use
US20050037415A1 (en) Methods for screening for transdominant effector peptides and RNA molecules
US6582899B1 (en) Methods for identifying agents that cause a lethal phenotype, and agents thereof
JP2003513670A (ja) ジフテリア毒素構築体を用いるスクリーニングのための方法および組成物
AU777489B2 (en) Methods for screening for transdominant effector peptides and RNA molecules
US20030157477A1 (en) Methods and reagents for identifying synthetic genetic elements
US20020025940A1 (en) Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and use for cellular assays in drug discovery
US6982313B2 (en) Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
HK1016997B (en) Methods for screening for transdominant effector peptides and rna molecules
US20070166769A1 (en) Bi-directionally cloned random cDNA expression vector libraries, compositions and methods of use
US20030054389A1 (en) Methods for identifying agents that induce a cellular phenotype, and compositions thereof
US7087382B1 (en) Methods for detecting polypeptides regulating signal transduction pathways
JP2009065909A (ja) 蛋白質核外輸送阻害物質のスクリーニング方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040123

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070306

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070706

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080527

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081202